The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Myeloproliferative Disorders

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Myeloproliferative Disorders


High impact information on Myeloproliferative Disorders


Chemical compound and disease context of Myeloproliferative Disorders


Biological context of Myeloproliferative Disorders


Anatomical context of Myeloproliferative Disorders


Gene context of Myeloproliferative Disorders


Analytical, diagnostic and therapeutic context of Myeloproliferative Disorders


  1. Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. Wang, J., Iwasaki, H., Krivtsov, A., Febbo, P.G., Thorner, A.R., Ernst, P., Anastasiadou, E., Kutok, J.L., Kogan, S.C., Zinkel, S.S., Fisher, J.K., Hess, J.L., Golub, T.R., Armstrong, S.A., Akashi, K., Korsmeyer, S.J. EMBO J. (2005) [Pubmed]
  2. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D.G., Lodish, H. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  3. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Villeval, J.L., Cohen-Solal, K., Tulliez, M., Giraudier, S., Guichard, J., Burstein, S.A., Cramer, E.M., Vainchenker, W., Wendling, F. Blood (1997) [Pubmed]
  4. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Hao, S.X., Ren, R. Mol. Cell. Biol. (2000) [Pubmed]
  5. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Xu, G., Nagano, M., Kanezaki, R., Toki, T., Hayashi, Y., Taketani, T., Taki, T., Mitui, T., Koike, K., Kato, K., Imaizumi, M., Sekine, I., Ikeda, Y., Hanada, R., Sako, M., Kudo, K., Kojima, S., Ohneda, O., Yamamoto, M., Ito, E. Blood (2003) [Pubmed]
  6. Role of Dok-1 and Dok-2 in leukemia suppression. Niki, M., Di Cristofano, A., Zhao, M., Honda, H., Hirai, H., Van Aelst, L., Cordon-Cardo, C., Pandolfi, P.P. J. Exp. Med. (2004) [Pubmed]
  7. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. Chan, I.T., Kutok, J.L., Williams, I.R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D.A., Jacks, T., Gilliland, D.G. J. Clin. Invest. (2004) [Pubmed]
  8. Quantitative effects of Nf1 inactivation on in vivo hematopoiesis. Zhang, Y., Taylor, B.R., Shannon, K., Clapp, D.W. J. Clin. Invest. (2001) [Pubmed]
  9. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders. Cooper, B., Ahern, D. J. Clin. Invest. (1979) [Pubmed]
  10. Adverse effect of erythropoietin in myeloproliferative disorders. Iki, S., Yagisawa, M., Ohbayashi, Y., Sato, H., Urabe, A. Lancet (1991) [Pubmed]
  11. Hydroxyurea-induced leg ulceration in 14 patients. Best, P.J., Daoud, M.S., Pittelkow, M.R., Petitt, R.M. Ann. Intern. Med. (1998) [Pubmed]
  12. Altered arachidonate metabolism by platelets in patients with myeloproliferative disorders. Okuma, M., Uchino, H. Blood (1979) [Pubmed]
  13. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Wolff, N.C., Ilaria, R.L. Blood (2001) [Pubmed]
  14. Platelet function and thromboxane synthesis in myeloproliferative disorders. Zahavi, M., Zahavi, J. Blood (1993) [Pubmed]
  15. Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody. Kyrtsonis, M.C., Kokoris, S.I., Kontopidou, F.N., Siakantaris, M.P., Kittas, C., Pangalis, G.A. Blood (2001) [Pubmed]
  16. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Kralovics, R., Buser, A.S., Teo, S.S., Coers, J., Tichelli, A., van der Maas, A.P., Skoda, R.C. Blood (2003) [Pubmed]
  17. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Jones, A.V., Kreil, S., Zoi, K., Waghorn, K., Curtis, C., Zhang, L., Score, J., Seear, R., Chase, A.J., Grand, F.H., White, H., Zoi, C., Loukopoulos, D., Terpos, E., Vervessou, E.C., Schultheis, B., Emig, M., Ernst, T., Lengfelder, E., Hehlmann, R., Hochhaus, A., Oscier, D., Silver, R.T., Reiter, A., Cross, N.C. Blood (2005) [Pubmed]
  18. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Hayashi, Y., Eguchi, M., Sugita, K., Nakazawa, S., Sato, T., Kojima, S., Bessho, F., Konishi, S., Inaba, T., Hanada, R. Blood (1988) [Pubmed]
  19. Identification of a human gene (HCK) that encodes a protein-tyrosine kinase and is expressed in hemopoietic cells. Quintrell, N., Lebo, R., Varmus, H., Bishop, J.M., Pettenati, M.J., Le Beau, M.M., Diaz, M.O., Rowley, J.D. Mol. Cell. Biol. (1987) [Pubmed]
  20. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. MacKenzie, K.L., Dolnikov, A., Millington, M., Shounan, Y., Symonds, G. Blood (1999) [Pubmed]
  21. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Popovici, C., Adélaïde, J., Ollendorff, V., Chaffanet, M., Guasch, G., Jacrot, M., Leroux, D., Birnbaum, D., Pébusque, M.J. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  22. Megakaryocytes from chronic myeloproliferative disorders show enhanced nuclear bFGF expression. Bock, O., Schlué, J., Lehmann, U., von Wasielewski, R., Länger, F., Kreipe, H. Blood (2002) [Pubmed]
  23. Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability. Engström, K.G., Löfvenberg, E. Blood (1998) [Pubmed]
  24. Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Mirza, A.M., Ezzat, S., Axelrad, A.A. Blood (1997) [Pubmed]
  25. Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions. Elefanty, A.G., Cory, S. Mol. Cell. Biol. (1992) [Pubmed]
  26. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Braun, B.S., Tuveson, D.A., Kong, N., Le, D.T., Kogan, S.C., Rozmus, J., Le Beau, M.M., Jacks, T.E., Shannon, K.M. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  27. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Guasch, G., Popovici, C., Mugneret, F., Chaffanet, M., Pontarotti, P., Birnbaum, D., Pébusque, M.J. Blood (2003) [Pubmed]
  28. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Gurbuxani, S., Vyas, P., Crispino, J.D. Blood (2004) [Pubmed]
  29. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Pardanani, A., Tefferi, A. Blood (2004) [Pubmed]
  30. Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders. Peeters, P., Wlodarska, I., Baens, M., Criel, A., Selleslag, D., Hagemeijer, A., Van den Berghe, H., Marynen, P. Cancer Res. (1997) [Pubmed]
  31. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Mahgoub, N., Taylor, B.R., Gratiot, M., Kohl, N.E., Gibbs, J.B., Jacks, T., Shannon, K.M. Blood (1999) [Pubmed]
  32. Progenitor cell transplantation for chronic myelogenous leukemia. Szatrowski, T.P. Semin. Oncol. (1999) [Pubmed]
  33. CD16 antigen density on neutrophils in chronic myeloproliferative disorders. Kabutomori, O., Iwatani, Y., Koh, T., Yanagihara, T. Am. J. Clin. Pathol. (1997) [Pubmed]
  34. Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Benesch, M., Deeg, H.J. Mayo Clin. Proc. (2003) [Pubmed]
  35. Increased low-density lipoprotein levels after splenectomy: a role for the spleen in cholesterol metabolism in myeloproliferative disorders. Aviram, M., Brook, J.G., Tatarsky, I., Levy, Y., Carter, A. Am. J. Med. Sci. (1986) [Pubmed]
WikiGenes - Universities